Category: Federal Forum Posters
Purpose: The introduction of direct-acting antivirals (DAA) has greatly improved sustained virologic response (SVR) rates in the treatment of hepatitis C. While adherence is a critical factor in treatment success, few studies have examined the effect of real-world adherence on the achievement of SVR12. The purpose of this study is to determine the impact of non-adherence to DAA therapy on achievement of SVR12 in a real-world clinic setting. The primary outcome will be to evaluate the correlation of adherence to DAA therapy with achievement of SVR12 in patients with chronic hepatitis C virus (HCV) infection.
Methods: The electronic medical record will be used to identify patients for inclusion based on treatment for HCV with ledipasvir/sofosbuvir, velpatasvir/sofosbuvir, or elbasvir/grazoprevir, during the fiscal year 2017 (October 01, 2016 - September 30, 2017). Veterans will be excluded if they were unable to be contacted at the end of the treatment, and if they received treatment for HCV with any other regimen other than those specified in the inclusion criteria. Pertinent data collected will include demographic data; history of substance abuse or unstable mental health diagnoses; HCV genotype and treatment history; presence of cirrhosis at baseline; DAA agent and duration of therapy; HCV viral load at baseline, SVR12, and all intervening follow up visits; number and percentage of missed doses of DAA therapy; side effects reported; number of concomitant medications; and presence of potentially-interacting medications. The primary outcome will be assessed using binomial logistic regression.
Results: Not applicable
Conclusion: Not applicable
Jessica Keels– PGY1 Pharmacy Resident, William Jennings Bryan Dorn Veterans Affairs Medical Center, West Columbia, SC